Abstract:To the Editor: Central nervous system (CNS) relapse is a devastating event of diffuse large B cell lymphoma (DLBCL). It occurs in 4%-7% of DLBCL in general and the rate is considerably higher in high-risk patients, resulting in a poor outcome.1 Effective methods of CNS prophylaxis have not yet been developed. In the past, intrathecal (IT) therapy had been widely used but its role has been questioned nowadays.2 Systemic high-dose MTX (methotrexate, HD MTX) has been proven effective in several studies. With IV MTX at a dose of 3-3.5 g/m2 is recommended and is often delivered on day 15 of RCHOP.3 This routine was efficacious but may delay or interrupt subsequent chemotherapy due to increased toxicity, especially for elderly patients. Although IV MTX could also be delivered every 2 to 3 weeks after the last R-CHOP course, it is better to adopt prophylactic measures early in the treatment course since CNS relapse mainly occurs within the first year (median: 6 months).2, 4 We herein report the result of our prospective, historic controlled study demonstrating that intravenous MTX at 1 g/m2 could significantly decrease the CNS relapse rate in high risk DLBCL patients. As IV MTX was delivered during RCHOP, it was a convenient regimen which did not increase admission times. From July 2015 to February 2017, 90 patients diagnosed of DLBCL with high CNS relapse risk were enrolled in our study and given IV MTX at a dose of 1 g/m2 to prevent CNS recurrence. A historical group of 91 patients with comparable age, sex, stage, ECOG and IPI who only received IT prophylaxis were used as controls. All these patients were similar in the following aspects: (a) age ≥ 18 years; (b) with high CNS risk, which was defined as involvement of more than one extranodal site, or involvement of particular extranodal sites such as bone marrow, breasts, testes, paranasal sinuses, epidural space, adrenal glands, kidney and female genital system; (c) first-line treatment with RCHOP; (d) complete staging work-up; and (e) absence of CNS involvement at presentation, confirmed by cerebral spinal fluid (CSF) examinations and MRI. Patients with primary mediastinal lymphoma, primary CNS lymphoma, intravascular large B-cell lymphoma, plasmablastic lymphoma, DLBCL leg-type, Burkitt lymphoma, gray zone or high-grade lymphomas with or without double/triple hit were excluded. Informed consent was obtained at the time of clinical trial enrolment in accordance with the Declaration of Helsinki. Note, CNS relapse was confirmed by positive CSF conventional cytology, CSF flow cytometry, or biopsy. For those who had clinical symptoms indicating a CNS involvement and typical lesions on MRI, we also considered a recurrence. In the intravenous prophylaxis group (study group), at least 1 course of IV MTX 1 g/m2 was given in concurrence with the RCHOP regimen. Rituximab was given on day 1, IV MTX on day 2 over 4 hours, and CHOP on day 3-7. Before IV MTX, rigorous hydration and urine alkylation was given. Methotrexate was rescued by leucovorin 24 hours after the infusion started. At the same time, the CSF concentration of MTX was tested in 33 patients. Patients in the study group also received IT cytarabine and dexamethasone, while patients in the control group (historic group) only received IT prophylaxis. The characteristics of these patients were displayed in supplementary data (Table S1). More patients in study group were in advanced stage (91.1% vs 76.9%, P = .014), with more than one extranodal site involvement (62.2% vs 44.0%, P = .017), and with kidney involvement (12.2% vs 3.3%, P = .023). There were more patients older than 60 years in the historic group (46.2% vs 31.1%, P = .047). Other clinical variables were comparable between two groups. All the patients were given RCHOP as initial therapy. Second line chemotherapy was chosen according to doctorʼs preference if disease progressed. Those who were under 65 years old, had an age-adjusted IPI > 1, and received complete remission during interim evaluation, underwent autologous hemopoietic stem cell transplantation (Auto-HSCT) as consolidation. Details of treatment were shown in Table S2. 83(91.2%) patients in the historic group had at least four courses of RCHOP while 86 (95.6%) patients in study group, with no significant difference found between them (P = .24). The proportion of patients underwent Auto-HSCT was also comparable, with 15 (16.5%) in the historic group and 20 (22.2%) in the study group (P = .352).There was no difference found in the course of IT prophylaxis between two groups (P = .961). In the study group, a median of four courses (range: 1-6) of intravenous MTX were given to the patients. We planned to give at least two courses of IV MTX in concurrence with two serial RCHOP from the second cycle, five(6%) patients only received one time of IV MTX because of mucositis (grade 3). Since the observation time was longer in the historic group (median 37 months, range 5-84 months) than the study group (median 27 months, range 5-64 months), we compared the 2-year CNS relapse rate, 2-year PFS and OS between them. The 2-year CNS relapse rate was 12.1% in the historic group and 1.1% in the study group (P = .003, Figure 1A). The relapse patterns were summarized in Table S3. The 2-year PFS and 2-year OS of the historic group was 58% and 82% separately, while it was 74% and 87% in the study group. There was a significant difference in the 2-year PFS (P = .028, Figure 1B) between the two groups, but wasnʼt in the 2-year OS (P = .300, Figure 1C). We also performed a multivariate logistic regression test for CNS relapse, which included prophylaxis strategies, CNS risk factors and age. The results indicated IV MTX was the only variable that affected CNS relapse (Table S4). The odds ratio (OR) was 14.675 (95% CI 1.804-119.359, P = .012). For 2-year PFS, multivariate COX regression was done and the results demonstrated that treatment (HR 2.148, 95% CI 1.257-3.670, P = .005), IPI≥4 (HR 0.398, 95% CI 0.173-0.919, P = .031) and stage III-IV (HR 0.329, 95% CI 0.112-0.962, P = .042) predicted disease progression (Table S5). We examined the CSF concentration of MTX 24 hours after infusion started in 33 patients. The median was 0.34 μmol/L (range: 0.04-1.6). After hydration and leucovorin rescue, the concentration of MTX could fall below 0.1 μmol/L in all cases 48 hours after infusion. A total of 332 courses of IV MTX were given to 90 patients. The most common side effects were mucositis, nephrotoxicity and hepatotoxicity. There were 38 (11.4%) cases of mucositis, with 32 (9.6%) in grade 1-2 and 6 (1.8%) in grade 3. Acute kidney injury happened in 16 (4.8%) courses, all of which were grade 1. Hepatotoxicity was found in 12 (3.6%) cases, with only 1 in grade 2, others were all grade 1. All these adverse events were expected and resolved quickly. The present study evaluated the effects of systemic treatment with intravenous MTX on CNS relapse and survival in high risk DLBCL patients in a real world setting. In the past, we used IT cytarabine and dexamethasone to prevent CNS relapse. But it turned out to be insufficient as the recurrence rate was high. The ineffectiveness of IT prophylaxis was also confirmed by two recent studies,5, 6 calling for new preventing strategy. For ethical reasons, random assignment of high-risk patients to untreated groups can be problematic, so we prospectively collected patients recieving intravenous MTX for prophylaxis and compared it to our historic population. As the immunochemotherapy and IT treatment were comparable in two groups, we drawn our conclusionthat intravenous methotrexate at an intermediate dose of 1 g/m2 incorporated to standard R-CHOP regimen is associated with decreased 2-year CNS recurrence risk (1.1% vs 12.1%, P = .003). As MTX was delivered on day 2 of R-MTX-CHOP therapy, this routine was convenient and did not increase the admission times, which was important for our patients because most of them had to fly from their hometown far away to our hospital for each cycle of treatment. Our 2-year PFS of 74% is also encouraging in a cohort of patients with a preponderance of high-risk features for systemic disease recurrence, including advanced stages (stage III-IV in 91.1%), high risk IPI scores (IPI≥4 in 37.8% of patients) and poor clinical performance (ECOG≥2 in 46.7%). Our result was controversial to the main stream opinion that systemic methotrexate lower than 3 g/m2 was unable to achieve adequate therapeutic levels in the CSF to yield significant benefit.7 Those conclusions, however, were mainly drawn from early studies in the 1990s, in which they did not find any significant difference in CNS relapse rate between chemotherapy with or without intermediate IV MTX, like the M-BACOS regimen for instance, which contained 1 g/m2 IV MTX.8 But we should notice that in the 1990s, the risk factors predicting CNS recurrence were not well defined yet. Patients in those studies were DLBCL in general and the percentage of high risk patients was not clear, so it was hard to get a significant difference between prophylaxis therapies, given the CNS relapse rate in the general population was low.8 Another point against our result is that CSF MTX level should be more than 1 μmol/L, as the CSF concentration in our patients did not meet this threshold. But the therapeutic concentration of CSF MTX came from experiences of prophylaxis in acute lymphocytic leukemia.9 The relapse patterns of these two diseases are quite different. As in ALL, meningeal is the site where relapse mainly occurs, while in DLBCL CNS involvement mostly happens in parenchymal. The concentration of MTX in the CSF could not represent the efficiency of this medicine to prevent parenchymal involvement. Prevention strategies of CNS relapse also learn a lot from the treatment of primary central nervous system (CNS) lymphoma, in which significant advances have been made nowadays. Novel insights into the pathophysiology of PCNSL led to introduction of targeted agents such as BTK inhibitor and immunomodulatory drugs into the salvage setting. In the recent study of Ayed et al., they analyzed records for patients with DLBCL treated with R2CHOP as frontline therapy in two clinical trials (NCT00670358, NCT00907348), and found the estimated 2-year CNS relapse rates by Kaplan-Meier method are 0.9% for the entire R2CHOP cohort and 5.0% for the high CNS-IPI risk group. This indicates incorporation of lenalidomide into RCHOP is associated with a lower-than-expected rate of CNS relapse.10 Limited by the small number of patients (only 25 CNS-IPI high risk patients), this conclusion needs further confirmation. We do agree that novel agents such as lenolidomide, ibrutinib and venetoclax might be effective in CNS prophylaxis, especially in elderly patients who could not tolerate IV MTX. But considering the cost of these new agents, IV MTX would still be the standard treatment in China. In conclusion, our prospective, historic controlled study in DLBCL patients with high CNS risk provided an effective, convenient, and safe regimen to prevent CNS relapse. The better 2-year PFS also indicated this is a promising strategy. Further study with more patients should be taken to validate our exploration. The authors declare no competing financial interests. W.Z. and D.B.Z. designed experiments, W.W. analyzed all the data, and wrote the first draft of the manuscript, Y.Z., L.Z., C.Y., J.F., H.C.C., M.C., X.X.C., J.L.Z., T.N.Z., D.M.H., and J.L. provided the data, W.Z., and D.B. Z., revised the final draft. All authors reviewed and edited the final manuscript before submission. Table S1. Epidemic and clinical characteristics of patients in two groups. Table S2. Treatment in two groups. Table S3. Patients who experienced CNS relapse in 2 years. Table S4. Multivariate logistic regression analyses of risk factors for CNS relapse. Table S5. Multivariate Cox regression analyses of risk factors for 2-year PFS. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Abstract:Introduction: Central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) is an uncommon yet often fatal complication with an overall survival (OS) of less than 6 months. According to the clinical risk model CNS-IPI, patients with 4-6 risk factors have a 2-year rate of CNS relapse of 10%. Involvement of certain extranodal sites such as testes or breast also confers increased risk, even with low-CNS-IPI. In high-risk patients, CNS prophylaxis is usually recommended, although the optimal regimen remains unclear. In this study, we examined the efficacy of different regimens on preventing CNS relapse in high-risk patients. Methods: We reviewed all newly diagnosed patients (pts) with DLBCL at Memorial Sloan Kettering Cancer Center from 2001 to 2017 treated with frontline rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (RCHOP) or RCHOP-like regimens. Patients with primary mediastinal lymphoma, HIV-positive or known CNS disease at diagnosis were excluded. High risk for CNS (HR-CNS) relapse was defined by high-CNS IPI (4-6 risk factors) or low-CNS IPI with testicular, breast, kidney/adrenal and/or bone marrow (BM) involvement. CNS prophylaxis was administered per physician preference. Results: We identified 2002 pts treated with RCHOP or RCHOP-like regimens. Among them, 569 (28%) were classified as HR-CNS relapse and were included in the study. Median age was 68 years (range 21-91) and 290 (51%) were male. The high-risk extranodal sites were: BM, n=118 (20%); kidney/adrenal, n=106 (18%); testes, n=51 (9%) and breast, n=47 (8%). 158 pts (28%) had more than 2 extranodal sites. Cell or origin determined by Hans algorithm was non-germinal center (GCB) (non-GCB) in 40%, GCB in 39% and missing in 21%. 284 pts (50%) received CNS prophylaxis: intrathecal (IT) methotrexate (MTX) and/or IT cytarabine, n= 245 (86%); or high-dose intravenous MTX (HD-MTX), n=40 (14%). Pts's characteristics are shown in Table 1. After a median follow-up of 5.6 years, CNS relapse was observed in 36 out of 569 pts with HR-CNS relapse (5-year risk 6.4%), of whom 14 (39%) had received prophylaxis (IT, n=12; HD-MTX, n=2). The risk of CNS relapse at 5 years in pts who received IT prophylaxis was 5.6% compared with 5.2% in pts who received intravenous HD-MTX. Pts with HR-CNS relapse who did not receive prophylaxis had a 5-year risk for CNS relapse of 7.6% (p=0.34) (Figure 1). Pts with non-GCB phenotype had a higher risk of CNS relapse compared with patients with GCB subtype (5-year risk of 10% vs. 2%) (p=0.03). The median time to CNS relapse was 9 months (range 6-110 months). Pts who received prophylaxis, (either IT or HD-MTX), relapsed later than patients who did not receive prophylaxis, with a median time to relapse of 19 months (range 7-55) vs. 8 months (range 6 to 110), respectively. The risk of CNS relapse at 1 year was lower for pts who received prophylaxis (IT or HD-MTX) compared to pts who did not, 1% vs. 3.2%, risk ratio (RR) 0.30 (95% CI; 0.07,0.68). However, over time the risk of CNS relapse became similar between prophylaxis and non-prophylaxis groups, with a 5-year risk of 5.8% vs. 7.6% (RR 0.76, CI 95%; 0.37, 1.55), respectively (Figure 2). CNS relapses were confined to the CNS (n=26, 72%) or included systemic relapsed in addition to CNS (n=10, 28%). CNS sites of relapse are detailed in table 2. Overall survival (OS) in patients with CNS relapse was worse than in pts who relapsed outside the CNS, with a 2-year OS of 24% (95% CI, 12%-40%) vs. 40% (95% CI, 31%-48%), respectively (p=0.002). Conclusion: In the era of chemoimmunochemotherapy, CNS prophylaxis tended to delay relapse rather than effectively preventing it. Although we did not detect differences in the efficacy between intrathecal and intravenous HD-MTX, larger studies are needed to better compare the efficacy of these two preventive modalities. Disclosures Noy: Medscape: Honoraria; Janssen: Consultancy; Prime Oncology: Honoraria; NIH: Research Funding; Pharamcyclics: Research Funding; Raphael Pharma: Research Funding. Horwitz:Corvus Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Corvus Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Mundipharma: Consultancy; Affimed: Consultancy; ADCT Therapeutics: Research Funding; Astex: Consultancy; Innate Pharma: Consultancy; Seattle Genetics: Consultancy, Research Funding; Miragen: Consultancy; Miragen: Consultancy; Kura: Consultancy; Kura: Consultancy; Innate Pharma: Consultancy; Infinity/Verastem: Consultancy, Research Funding; Trillium: Research Funding; Celgene: Consultancy, Research Funding; Portola: Consultancy; Millennium/Takeda: Consultancy, Research Funding; Millennium/Takeda: Consultancy, Research Funding; Portola: Consultancy; Trillium: Research Funding; Celgene: Consultancy, Research Funding; Astex: Consultancy; Infinity/Verastem: Consultancy, Research Funding; Kura: Consultancy; Miragen: Consultancy; Affimed: Consultancy; Millennium/Takeda: Consultancy, Research Funding; Aileron: Research Funding; Seattle Genetics: Consultancy, Research Funding; Mundipharma: Consultancy; Celgene: Consultancy, Research Funding; Kyowa Hakko Kirin: Consultancy; Seattle Genetics: Consultancy, Research Funding; Innate Pharma: Consultancy; Trillium: Research Funding; Forty-Seven: Research Funding; Aileron: Research Funding; Aileron: Research Funding; Astex: Consultancy; Forty-Seven: Research Funding; Miragen: Consultancy; Infinity/Verastem: Consultancy, Research Funding; Forty-Seven: Research Funding; Infinity/Verastem: Consultancy, Research Funding; Kyowa Hakko Kirin: Consultancy; Mundipharma: Consultancy; Corvus Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Astex: Consultancy; Trillium: Research Funding; Celgene: Consultancy, Research Funding; ADCT Therapeutics: Research Funding; Kura: Consultancy; Millennium/Takeda: Consultancy, Research Funding; Affimed: Consultancy; Portola: Consultancy; Seattle Genetics: Consultancy, Research Funding; Aileron: Research Funding; Forty-Seven: Research Funding; Innate Pharma: Consultancy; Kyowa Hakko Kirin: Consultancy; Portola: Consultancy; Affimed: Consultancy; ADCT Therapeutics: Research Funding; Corvus Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; ADCT Therapeutics: Research Funding; Mundipharma: Consultancy; Kyowa Hakko Kirin: Consultancy. Palomba:Hemedicus: Other: Immediate Family Member, Speakers Bureau ; Merck & Co Inc.: Other: Immediate Family Member, Consultancy (includes expert testimony); Seres Therapeutics: Other: Immediate Family Member, Equity Ownership and Membership on an entity's Board of Directors or advisory committees; STRAXIMM: Other: Immediate Family Member, Membership on an entity's Board of Directors or advisory committees; Kite Pharmaceuticals: Other: Immediate Family Member, Membership on an entity's Board of Directors or advisory committees; Pharmacyclics: Membership on an entity's Board of Directors or advisory committees; Noble Insights: Consultancy; Evelo: Other: Immediate family member, Equity Ownership; MSK (IP for Juno and Seres): Other: Immediate Family Member, Patents & Royalties - describe: intellectual property rights . Matasar:Juno Therapeutics: Consultancy; Merck: Consultancy, Equity Ownership; Genentech, Inc.: Consultancy, Honoraria, Other: Travel, accommodation, expenses , Research Funding; Bayer: Consultancy, Honoraria, Other; Roche: Consultancy, Honoraria, Other: Travel, accommodation, expenses , Research Funding; Bayer: Other: Travel, accommodation, expenses; Janssen: Honoraria, Research Funding; Pharmacyclics: Consultancy, Honoraria, Research Funding; Teva: Consultancy; Rocket Medical: Consultancy, Research Funding; Seattle Genetics: Consultancy, Honoraria, Other: Travel, accomodation, expenses, Research Funding; Daiichi Sankyo: Consultancy; GlaxoSmithKline: Honoraria, Research Funding. Straus:Hope Funds for Cancer Research: Membership on an entity's Board of Directors or advisory committees; Hope Funds for Cancer Research: Membership on an entity's Board of Directors or advisory committees; Elsevier (PracticeUpdate): Consultancy, Honoraria; Seattle Genetics: Consultancy, Honoraria; Hope Funds for Cancer Research: Membership on an entity's Board of Directors or advisory committees. Batlevi:Juno Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees. Moskowitz:Incyte: Research Funding; miRagen Therapeutics Inc: Consultancy, Research Funding; ADC Therapeutics: Consultancy; Seattle Genetics: Consultancy, Honoraria, Research Funding; Kyowa Hakko Kirin Pharma: Consultancy, Research Funding; Seattle Genetics: Consultancy, Honoraria, Research Funding; Merck: Research Funding; Erytech Pharma: Consultancy; ADC Therapeutics: Consultancy; Erytech Pharma: Consultancy; Kyowa Hakko Kirin Pharma: Consultancy, Research Funding; Merck: Research Funding; Incyte: Research Funding; Incyte: Research Funding; Erytech Pharma: Consultancy; miRagen Therapeutics Inc: Consultancy, Research Funding; Merck: Research Funding; Cell Medica: Consultancy; Erytech Pharma: Consultancy; Incyte: Research Funding; Takeda Pharmaceuticals: Consultancy; Cell Medica: Consultancy; Takeda Pharmaceuticals: Consultancy; Bristol-Myers Squibb: Consultancy, Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding; Incyte: Research Funding; Cell Medica: Consultancy; Cell Medica: Consultancy; miRagen Therapeutics Inc: Consultancy, Research Funding; Cell Medica: Consultancy; Takeda Pharmaceuticals: Consultancy; Takeda Pharmaceuticals: Consultancy; Incyte: Research Funding; miRagen Therapeutics Inc: Consultancy, Research Funding; Takeda Pharmaceuticals: Consultancy; Kyowa Hakko Kirin Pharma: Consultancy, Research Funding; Takeda Pharmaceuticals: Consultancy; miRagen Therapeutics Inc: Consultancy, Research Funding; Incyte: Research Funding; Takeda Pharmaceuticals: Consultancy; Incyte: Research Funding; ADC Therapeutics: Consultancy; ADC Therapeutics: Consultancy; ADC Therapeutics: Consultancy; Seattle Genetics: Consultancy, Honoraria, Research Funding; Kyowa Hakko Kirin Pharma: Consultancy, Research Funding; Takeda Pharmaceuticals: Consultancy; Seattle Genetics: Consultancy, Honoraria, Research Funding; Cell Medica: Consultancy; Takeda Pharmaceuticals: Consultancy; Seattle Genetics: Consultancy, Honoraria, Research Funding; Seattle Genetics: Consultancy, Honoraria, Research Funding; Kyowa Hakko Kirin Pharma: Consultancy, Research Funding; Kyowa Hakko Kirin Pharma: Consultancy, Research Funding; Seattle Genetics: Consultancy, Honoraria, Research Funding; Merck: Research Funding; Seattle Genetics: Consultancy, Honoraria, Research Funding; Merck: Research Funding; Merck: Research Funding; Merck: Research Funding; Merck: Research Funding; Erytech Pharma: Consultancy; Bristol-Myers Squibb: Consultancy, Research Funding; Merck: Research Funding; miRagen Therapeutics Inc: Consultancy, Research Funding; miRagen Therapeutics Inc: Consultancy, Research Funding; Cell Medica: Consultancy; miRagen Therapeutics Inc: Consultancy, Research Funding; ADC Therapeutics: Consultancy; Bristol-Myers Squibb: Consultancy, Research Funding; Seattle Genetics: Consultancy, Honoraria, Research Funding; Seattle Genetics: Consultancy, Honoraria, Research Funding; Merck: Research Funding; Merck: Research Funding; Cell Medica: Consultancy; Cell Medica: Consultancy; Cell Medica: Consultancy; Incyte: Research Funding; Incyte: Research Funding; ADC Therapeutics: Consultancy; Incyte: Research Funding; ADC Therapeutics: Consultancy; ADC Therapeutics: Consultancy; Bristol-Myers Squibb: Consultancy, Research Funding; Erytech Pharma: Consultancy; miRagen Therapeutics Inc: Consultancy, Research Funding; Erytech Pharma: Consultancy; Cell Medica: Consultancy; Kyowa Hakko Kirin Pharma: Consultancy, Research Funding; miRagen Therapeutics Inc: Consultancy, Research Funding; Seattle Genetics: Consultancy, Honoraria, Research Funding; Takeda Pharmaceuticals: Consultancy; Erytech Pharma: Consultancy; Erytech Pharma: Consultancy; miRagen Therapeutics Inc: Consultancy, Research Funding; Erytech Pharma: Consultancy; ADC Therapeutics: Consultancy; Cell Medica: Consultancy; ADC Therapeutics: Consultancy; Erytech Pharma: Consultancy; miRagen Therapeutics Inc: Consultancy, Research Funding; miRagen Therapeutics Inc: Consultancy, Research Funding; Seattle Genetics: Consultancy, Honoraria, Research Funding; ADC Therapeutics: Consultancy; ADC Therapeutics: Consultancy; Bristol-Myers Squibb: Consultancy, Research Funding; ADC Therapeutics: Consultancy; Erytech Pharma: Consultancy; Bristol-Myers Squibb: Consultancy, Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding; Erytech Pharma: Consultancy; Bristol-Myers Squibb: Consultancy, Research Funding; Incyte: Research Funding; miRagen Therapeutics Inc: Consultancy, Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding; Kyowa Hakko Kirin Pharma: Consultancy, Research Funding; Merck: Research Funding; Kyowa Hakko Kirin Pharma: Consultancy, Research Funding; Takeda Pharmaceuticals: Consultancy; Merck: Research Funding; Seattle Genetics: Consultancy, Honoraria, Research Funding; Cell Medica: Consultancy; Bristol-Myers Squibb: Consultancy, Research Funding; Merck: Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding; ADC Therapeutics: Consultancy; Erytech Pharma: Consultancy; Bristol-Myers Squibb: Consultancy, Research Funding; Incyte: Research Funding; miRagen Therapeutics Inc: Consultancy, Research Funding; Kyowa Hakko Kirin Pharma: Consultancy, Research Funding; Kyowa Hakko Kirin Pharma: Consultancy, Research Funding; Erytech Pharma: Consultancy; Takeda Pharmaceuticals: Consultancy; Kyowa Hakko Kirin Pharma: Consultancy, Research Funding; Incyte: Research Funding; Cell Medica: Consultancy; Takeda Pharmaceuticals: Consultancy; Takeda Pharmaceuticals: Consultancy; Kyowa Hakko Kirin Pharma: Consultancy, Research Funding; Cell Medica: Consultancy; Takeda Pharmaceuticals: Consultancy; Kyowa Hakko Kirin Pharma: Consultancy, Research Funding; Seattle Genetics: Consultancy, Honoraria, Research Funding; Kyowa Hakko Kirin Pharma: Consultancy, Research Funding; Incyte: Research Funding; Seattle Genetics: Consultancy, Honoraria, Research Funding; Merck: Research Funding. von Keudell:Bayer: Consultancy; Genentech: Consultancy; Pharmacyclics: Consultancy; Pharmacyclics: Consultancy; Genentech: Consultancy; Bayer: Consultancy. Dogan:Roche: Consultancy, Research Funding; Corvus Pharmaceuticals: Consultancy; Seattle Genetics: Consultancy; Celgene: Consultancy; Takeda: Consultancy; Novartis: Consultancy. Zelenetz:DAVA Oncology: Consultancy, Membership on an entity's Board of Directors or advisory committees; Bayer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees; DAVA Oncology: Consultancy, Membership on an entity's Board of Directors or advisory committees; Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees; Verastem: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Morphosys: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pharmacyclics/AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pharmacyclics/AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Bayer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees; DAVA Oncology: Consultancy, Membership on an entity's Board of Directors or advisory committees; Genentech/Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees; Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees; Morphosys: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Morphosys: Consultancy, Membership on an entity's Board of Directors or advisory committees; MEI Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees; Astra-Zeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees; MEI Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pharmacyclics/AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Beigene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Astra-Zeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees; Verastem: Consultancy, Membership on an entity's Board of Directors or advisory committees; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees; Morphosys: Consultancy, Membership on an entity's Board of Directors or advisory committees; Verastem: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees; Genentech/Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees; Genentech/Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Verastem: Consultancy, Membership on an entity's Board of Directors or advisory committees; Morphosys: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pharmacyclics/AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Verastem: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pharmacyclics/AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pharmacyclics/AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; DAVA Oncology: Consultancy, Membership on an entity's Board of Directors or advisory committees; Genentech/Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees; Verastem: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Morphosys: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Beigene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Genentech/Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees. Younes:BMS: Research Funding; AstraZeneca: Research Funding; Genentech: Research Funding; Roche: Consultancy, Honoraria, Research Funding; Xynomics: Consultancy; Syndax: Research Funding; Epizyme: Consultancy, Honoraria; HCM: Consultancy; Celgene: Consultancy, Honoraria; Takeda: Honoraria; Abbvie: Honoraria; Merck: Honoraria, Research Funding; Curis: Honoraria, Research Funding; Pharmacyclics: Research Funding; Janssen: Honoraria, Research Funding; Biopath: Consultancy.

Factors Influencing Physician Discretion to Administer CNS Prophylaxis in Diffuse Large B Cell Lymphoma: A Single Institution Retrospective Study

Comparison of standardized prophylactic high-dose and intrathecal methotrexate for DLBCL with a high risk of CNS relapse

Model for Predicting Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma and Discussion of Prophylaxis Measures.

Integration of Cell of Origin into the Clinical CNS International Prognostic Index Improves CNS Relapse Prediction in DLBCL.

CNS Prophylaxis in Diffuse Large B-Cell Lymphoma: A Common Toxic Clinical Practice Based on Abundant Opinion, Despite Evidence Suggesting Futility

Efficacy of intravenous high-dose methotrexate in preventing relapse to the central nervous system in R-CHOP(-like)-treated, high-risk, diffuse large B-cell lymphoma patients and its effect on mortality: a systematic review and meta-analysis

High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma

Recent updates on central nervous system prophylaxis in patients with high-risk diffuse large B-cell lymphoma

Optimization of high-dose methotrexate prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma: a multicenter analysis

Central nervous system (CNS) prophylaxis in antiCD20-CHOP treated DLBCL at intermediate to high risk for CNS relapse: A systematic review and meta-analysis

Efficacy of Intrathecal Delivery of Peptide-Pulsed Type 1 Conventional Dendritic Cell Vaccine for the Treatment of Breast Cancer-Associated Leptomeningeal Disease in Preclinical Models.

High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma

Intravenous Methotrexate at a Dose of 1 G/m2 Incorporated into RCHOP Prevented CNS Relapse in High‐risk DLBCL Patients: A Prospective, Historic Controlled Study

Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of CNS Relapse Treated in the Rituximab Era

Incidence of Central Nervous System Relapse in Primary Mediastinal Large B-Cell Lymphoma: Implications for Central Nervous System Prophylaxis

Outcome of patients with diffuse large B-cell lymphoma and testicular involvement – real world data

Limited efficacy of high-dose methotrexate to prevent the central nervous system relapse in patients with IVLBCL

Low Rates of CNS Relapse in High Risk DLBCL Patients Treated with R-CODOX-M and R-IVAC: Results from a Phase 2 UK NCRI/Bloodwise Trial

High-dose methotrexate and rituximab induction regimen in immunocompetent patients with primary CNS lymphoma: a retrospective single-center study of survival predictors

Phase II, Single-Center, Prospective Study of Intrathecal Thiotepa for the Prophylaxis of Secondary Central Nervous System Involvement in Highly Aggressive B-Cell Lymphoma

Efficacy of intrathecal chemotherapy in patients with central nervous system involvement of hematological malignancies: a retrospective analysis